One or more adverse effects occurred in 10 of the 16 patients (62.5%) who received treatment: 6 cases of neutropenia (median neutrophil count 870/mmc, range 530–920/mmc), 3 of anemia (median Hb value 8.3 g/dL, range 7–8.6 g/dL), 3 of hypertransaminasemia (median ALT 85 U/L, range 58–381 U/L) and 1 of skin rash. This evidence concerns the gene GSTM1 and Decreased total neutrophil count.